Taysha Gene Therapies, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of severe monogenic diseases of the central nervous system. The company primarily develops TSHA-120 for the treatment of giant...
22 insider purchases on record · latest filing 2025-06-03.
Insiders have also filed 43 sale transactions at TSHA.